

To the shareholders of Molecular Partners AG (the Company)

Invitation to the Annual General Meeting 2024

Wednesday, April 17, 2024, 9:00 a.m. (Admission from 8:30 a.m.)
JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland

Agenda and Proposals of the Board of Directors

1. Approval of the Annual Review, the IFRS Consolidated Financial Statements and the Annual Financial Statements for the Financial Year 2023

The Board of Directors proposes to approve the Annual Review 2023, the IFRS Consolidated Financial Statements 2023 and the Annual Financial Statements 2023.

Explanations

The Annual Report 2023 includes the Annual Review, the IFRS Consolidated Financial Statements (pages 69ff. of the Annual Report 2023) and the Molecular Partners AG Financial Statements (pages 115ff. of the Annual Report 2023). According to Art. 698 para. 2 items 3 and 4 of the Swiss Code of Obligations (CO) and Art. 8 lit. c and d of the Articles of Incorporation of the Company, the general meeting is responsible for approving the Annual Review, the Consolidated Financial Statements and the Financial Statements. The approval of the Financial Statements is a prerequisite for the resolution on the appropriation of available earnings.

2. Consultative Vote on the Compensation Report

The Board of Directors proposes to approve the Compensation Report 2023 in a consultative vote.

Explanations

The Compensation Report 2023 is included in the Annual Report 2023 (pages 51ff.). According to Art. 735 para. 3 item 4 of the CO and Art. 28 para. 5 of the Articles of Incorporation of the Company, the Board of Directors submits the Compensation Report to shareholders for a separate consultative vote in addition to the binding approvals of the compensation amounts under agenda item 10 if variable compensation is approved prospectively.

3. Appropriation of Net Loss

The Board of Directors proposes to carry forward and not to offset, the net loss for 2023 of CHF 56,285,222, thereby bringing the loss carried forward position from CHF 92,511,521 to CHF 148,796,743.

Explanations

According to Art. 698 para. 2 item 4 and Art. 674 of the CO as well as Art. 8 lit. d of the Articles of Incorporation of the Company, the general meeting is responsible for approving the appropriation of available earnings or net loss.

4. Appropriation of Reserves

The Board of Directors proposes to transfer CHF 148,000,000 from the sub-position "Reserves from capital contributions" within the free reserves to the "Reserves from capital contributions" within the legal capital reserves.

Explanations

To avoid any potential set-off of free capital contribution reserves with losses as a result of a revision of the Swiss Code of Obligations entered into force on 1 January 2023, the Board of Directors proposes to re-transfer the reserves as set out above.

5. Discharge of the Board of Directors and the Management Board

The Board of Directors proposes that its members and the members of the Management Board be granted discharge for their activities in the financial year 2023.

Explanations

According to Art. 698 para. 2 item 7 of the Swiss CO and Art. 8 lit. f of the Articles of Incorporation of the Company, the general meeting is responsible for granting of discharge to the members of the Board of Directors and the Management Board. With the discharge of the members of the Board of Directors and the Management Board, the Company as well as the approving shareholders declare that they will no longer hold accountable the persons to whom discharge is granted responsible for events from the past financial year that were brought to the attention of the general meeting.

6. Amendment of Articles of Incorporation

The Board of Directors proposes to amend the articles 3a and 3b of the Articles of Incorporation¹ of the Company as set out below. (Insertions are marked in **bold** and deletions are ~~crossed out~~).

6.1 Article 3a - Capital Range

The Board of Directors proposes to amend Art. 3a of the Articles of Incorporation as follows:

Article 3a- Present version

Authorized Share Capital

- 1 The board of directors is authorized to increase the share capital, at any time until April 13, 2024, by a maximum amount of CHF 457,316.20 by issuing a maximum of 4,573,162 fully paid up registered shares with a par value of CHF 0.10 each. An increase of the share capital in partial amounts shall be permissible.

- 2 The acquisition of shares and each subsequent transfer of the shares shall be subject to the restrictions of Article 5 of these Articles of Incorporation.
- 3 The board of directors shall determine the issue price, the type of payment, the time of the issuance, the conditions for the exercise of the preemptive rights and the date from which the shares carry the right to dividends. The board of directors can issue new shares by means of an underwriting by a bank or another third party with a subsequent offer of these shares to the existing shareholders or third parties (if the preemptive rights of the existing shareholders have been denied or not been duly exercised). The board of directors is authorized to permit, to restrict or to deny the trade of preemptive rights. The board of directors may permit preemptive rights that have been granted but not exercised to expire or it may place these rights respectively the shares as to which preemptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interest of the Company.

Article 3a - Requested new version

~~Authorized Share Capital~~ Capital Range

- 1 ~~The board of directors is authorized to increase the share capital, at any time until April 13, 2024, by a maximum amount of CHF 457,316.20 by issuing a maximum of 4,573,162 fully paid up registered shares with a par value of CHF 0.10 each. An increase of the share capital in partial amounts shall be permissible.~~ **The Company has a capital range ranging from CHF 3,635,429.70 (lower limit) to up to CHF 5,453,144.55 (upper limit). The board of directors shall be authorized within the capital range to increase or reduce the share capital once or several times and in any amounts or to acquire or dispose of shares directly or indirectly, until April 17, 2029 or until an earlier expiry of the capital range. The capital increase or reduction may be effected by issuing fully paid-in registered shares and cancelling registered shares, as applicable, or by increasing or reducing the par value of the existing shares within the limits of the capital range or by simultaneous reduction and re-increase of the share capital.**
- 2 ~~The acquisition of the new shares and as well as any~~ **In the event of an issue of shares, the subscription and** ~~The acquisition of the new shares and as well as any~~ each subsequent transfer of the shares shall be subject to the restrictions of Article 5 of these Articles of Incorporation.
- 3 ~~The board of directors shall determine the issue price, the type of payment, the time of the issuance, the conditions for the exercise of the preemptive rights and the date from which the shares carry the right to dividends. The board of directors can issue new shares by means of an underwriting by a bank or another third party with a subsequent offer of these shares to the existing shareholders or third parties (if the preemptive rights of the existing shareholders have been denied or not been duly exercised). The board of directors is authorized to permit, to restrict or to deny the trade of preemptive rights. The board of directors may permit preemptive rights that have been granted but not exercised to expire or it may place these rights respectively the shares as to which preemptive rights have been granted but not exercised, at market conditions or use them for other purposes in the interest of the Company.~~ **In the event of a capital increase within the capital range, the board of directors shall, to the extent necessary,**

¹ <https://investors.molecularpartners.com/corporate-governance/documents-and-charters>

- determine the issue price, the type of contribution (including cash contributions, contributions in kind, set-off and conversion of reserves or of profit carried forward into share capital), the date of issue, the conditions for the exercise of subscription rights and the beginning date for dividend entitlement. In this regard, the board of directors may issue new shares by means of a firm underwriting through a financial institution, a syndicate of financial institutions or another third party and a subsequent offer of these shares to the existing shareholders or third parties (if the subscription rights of the existing shareholders have been withdrawn or have not been duly exercised). The board of directors is entitled to permit, to restrict or to exclude the trade with subscription rights. It may permit the expiration of subscription rights that have not been duly exercised, or it may place such rights or shares as to which subscription rights have been granted, but not duly exercised, at market conditions or may use them otherwise in the interest of the Company.**
- 4 The board of directors is further authorized to restrict or deny the preemptive rights of shareholders and to allocate them to third parties:
- for the acquisition of companies, parts of companies or participations, for the acquisition of products, intellectual property or licenses, or for investment projects or for the financing or refinancing of such transactions through a placement of shares; or
 - for the purpose of broadening the shareholder constituency or in connection with a listing of shares on domestic or foreign stock exchanges; or
 - if the issue price of the new Shares is determined by reference to the market price; or
 - for purposes of granting an over-allotment option (Greenshoe) of up to 20% of the total number of Shares in a placement or sale of Shares to the respective initial purchasers or underwriters; or
 - following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to the other shareholders a takeover offer recommended by the board of directors; or
 - for the defense of an actual, threatened or potential takeover bid, in relation to which the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders.
- 4 ~~The board of directors is further authorized to restrict or deny the preemptive rights of shareholders and to allocate them to third parties.~~ **In the event of a share issue the board of directors is authorized to withdraw or restrict subscription rights of existing shareholders and allocate such rights to third parties, the Company or any of its group companies:**
- for the acquisition of companies, parts of companies or participations, for the acquisition of products, intellectual property or licenses, or for investment projects or for the financing or refinancing of such transactions through a placement of shares; or
 - for the purpose of broadening the shareholder constituency **of the Company in certain financial or investor markets, for purposes of the participation of strategic partners including financial investors**, or in connection with a listing of **new** shares on domestic or foreign stock exchanges; or
 - if the issue price of the new Shares is determined by reference to the market price; or
 - for purposes of granting an over-allotment option (Greenshoe) of up to 20% of the total number of Shares in a placement or sale of Shares to the respective initial purchasers or underwriters; or
 - following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 15% of the share capital registered in the commercial register without having submitted to ~~the~~ **all** other shareholders a takeover offer recommended by the board of directors; or
 - for the defense of an actual, threatened or potential takeover bid, in relation to which the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the shareholders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair to the shareholders; **or**
 - for raising equity capital in a fast and flexible manner, which would not be possible, or would only be possible with great difficulty or at significantly less favorable conditions, without the exclusion of the subscription rights of existing shareholders; or**
 - for the participation of members of the board of directors, members of the Executive Committee, employees, contractors, consultants or other persons performing services for the benefit of the Company or any of its group companies.**

- 5 *After a change of the par value, new shares shall be issued within the capital range with the same par value as the existing shares.*
- 6 *If the share capital increases as a result of an increase from conditional capital pursuant to Article 3b and Article 3c of these Articles of Incorporation, the upper limit of the capital range shall increase in an amount corresponding to such increase in the share capital.*
- 7 *In the event of a reduction of the share capital within the capital range, the board of directors shall, to the extent necessary, determine the use of the reduction amount. The board of directors may also use the reduction amount for the partial or full elimination of a share capital shortfall in the sense of Article 653p CO or may, in the sense of Article 653q CO, simultaneously reduce and increase the share capital to at least the previous amount.*

Explanations

With the Swiss corporate law reform, the instrument of authorized share capital was replaced by the instrument of a capital range. Under a capital range, the general meeting authorizes the Board of Directors to increase or reduce the share capital within a certain range. The authorization is limited by law to five years.

In order to replace the authorized capital which expires on April 13, 2024 and no longer exists under the new law, the Board of Directors proposes to introduce a capital range for a maximum of five years in Art. 3a of the Articles of Incorporation. The upper and lower limit of the capital range shall be 150% and 100% of the share capital currently registered in the commercial register. As under the previous authorized capital, the Board of Directors shall have the right to restrict or withdraw shareholders' subscription rights in the event of an issue of shares within the capital range. The reasons for the restriction or withdrawal of subscription rights remain the same as under the previous authorized capital.

The capital range is intended to provide a reasonable level of financial flexibility which is required for a clinical stage biotech company.

6.2 Article 3b - Conditional Share Capital for Employee Participation

The Board of Directors proposes to amend Art. 3b of the Articles of Incorporation as follows:

Article 3b- Present version

Conditional Share Capital for Employee Participation

- 1 The share capital may be increased in an amount not to exceed CHF 105,337.20 through the issuance of up to 1,053,372 fully paid up registered shares with a par value of CHF 0.10 per share through the direct or indirect issuance of shares, options or preemptive rights thereof granted to employees and members of the board of directors of the Company or its subsidiaries as well as to members of any advisory boards.
- 2 The preemptive rights and advance subscription rights of the shareholders of the Company shall be excluded in connection with the issuance of any shares, options or preemptive rights thereof. Shares, options or preemptive rights thereof shall be issued in accordance with one or more participation plans and/or policies to be issued by the board of directors and in accordance with Section 4 of these Articles of Incorporation.
- 3 The new shares directly or indirectly acquired by employees, members of the board of directors of the Company or its subsidiaries or members of any advisory boards in connection with an employee participation program and any subsequent transfer of such shares shall be restricted by Article 5 of these Articles of Incorporation.

Article 3b - Requested new version

Conditional Share Capital for Employee Participation

- 1 The share capital may be increased in an amount not to exceed CHF ~~105,337.20~~**400,000** through the issuance of up to ~~1,053,372~~**4,000,000** fully paid up registered shares with a par value of CHF 0.10 per share through the direct or indirect issuance of shares, options or preemptive rights thereof granted to employees and members of the board of directors of the Company or its subsidiaries as well as to members of any advisory boards.
- 2 The preemptive rights and advance subscription rights of the shareholders of the Company shall be excluded in connection with the issuance of any shares, options or preemptive rights thereof. Shares, options or preemptive rights thereof shall be issued in accordance with one or more participation plans ~~and/or~~ **or resolutions** to be issued by the board of directors **or, to the extent delegated to it, the compensation committee** and in accordance with Section 4 of these Articles of Incorporation.
- 3 ~~The new shares directly or indirectly acquired by employees, members of the board of directors of the Company or its subsidiaries or members of any advisory boards in connection with an employee participation program and any subsequent transfer of such shares shall be restricted by Article 5 of these Articles of Incorporation.~~**The declaration of acquisition of the shares based on this Article 3b shall refer to this Article 3b and be made in a form that allows proof by text. A waiver of the right to**

acquire shares based on this Article 3b may also occur informally or by lapse of time; this also applies to the waiver of the exercise and forfeiture of this right.

- 4 The new shares directly or indirectly acquired by employees, members of the board of directors of the Company or its subsidiaries or members of any advisory boards in connection with an employee participation program and any subsequent transfer of such shares shall be restricted by Article 5 of these Articles of Incorporation.

Explanations

The Board of Directors proposes to increase the conditional share capital for employee participation according to Art. 3b of the Articles of Incorporation for the issuance of shares to employees and members of the Board of Directors of the Company or its subsidiaries as well as to members of any advisory boards from CHF 105,337.20 to CHF 400,000. This increase is intended to enable the Board of Directors to implement its compensation policy, which is designed to attract, motivate and retain its employees, members of the Board of Directors and members of advisory boards.

7. Re-Elections to the Board of Directors as well as the Nomination and Compensation Committee

7.1 Re-Elections to the Board of Directors

The Board of Directors proposes the re-elections of:

- 7.1.1 William (Bill) Burns;
- 7.1.2 Agnete B. Fredriksen;
- 7.1.3 Dominik Höchli;
- 7.1.4 Steven H. Holtzman;
- 7.1.5 Sandip Kapadia;
- 7.1.6 Vito J. Palombella;
- 7.1.7 Michael Vasconcelles; and
- 7.1.8 Patrick Amstutz;

each as a member of the Board of Directors for a term of office of one year until the conclusion of the annual general meeting 2025. All re-elections are held individually.

Explanations

According to Art. 698 para. 2 item 2 of the CO and Art. 8 lit. b of the Articles of Incorporation of the Company, the general meeting is responsible for the election of the members of the Board of Directors. The term of office of the members of the Board of Directors is limited by law to one year. The members of the Board of Directors are each (re-)elected individually. For biographical details on the candidates please refer to the Company's website² and on pages 36ff. of the Annual Report 2023. Please note that Patrick Amstutz as CEO of the Company is not and will not be member of any committee of the Board of Directors.

7.2 Re-Election of the Chairman of the Board of Directors

The Board of Directors proposes the re-election of William (Bill) Burns as Chairman of the Board of Directors for a term of office of one year until the conclusion of the annual general meeting 2025.

Explanations

According to Art. 698 para. 3 item 1 and Art. 712 para. 1 CO and Art. 8 lit. b of the Articles of Incorporation of the Company, the general meeting is responsible for the election of the Chairman of the Board of Directors. His term of office is limited by law to one year.

² <https://www.molecularpartners.com/about-us/>

7.3 Re-Elections to the Nomination and Compensation Committee

The Board of Directors proposes the re-elections of:

- 7.3.1 William (Bill) Burns;
- 7.3.2 Steven H. Holtzman; and
- 7.3.3 Michael Vasconcelles;

each as a member of the Nomination and Compensation Committee, for a term of office of one year until the conclusion of the annual general meeting 2025. All re-elections are held individually.

Explanations

According to Art. 698 para. 3 item 2 and Art. 733 para. 1 CO as well as Art. 8 lit. b of the Articles of Incorporation of the Company, the general meeting is responsible for the election of the members of the Nomination and Compensation Committee. Their term of office is limited by law to one year. Only members of the Board of Directors may be elected. If William (Bill) Burns is re-elected, the Board of Directors intends to re-appoint him as chairperson of the Nomination and Compensation Committee.

8. **Re-Election of the Statutory Auditors**

The Board of Directors proposes to re-elect KPMG AG, Zurich, as statutory auditors for the financial year 2024.

Explanations

According to Art. 698 para. 2 item 2 CO as well as Art. 8 lit. b of the Articles of Incorporation of the Company, the general meeting is responsible for the election of the Statutory Auditors. KPMG AG, Zurich, has confirmed that it has the necessary independence to carry out the mandate.

9. **Re-Election of the Independent Proxy**

The Board of Directors proposes to re-elect Anwaltskanzlei Keller AG, Zurich, as the independent proxy for a term of office until the conclusion of the annual general meeting 2025.

Explanations

According to Art. 689c para. 1 and Art. 698 para. 3 item 3 CO as well as Art. 8 lit. b of the Articles of Incorporation of the Company, the general meeting is responsible for the election of the independent proxy. Its term of office is limited by law to one year. Anwaltskanzlei Keller AG, Zurich, has confirmed that it has the necessary independence to carry out the mandate.

10. **Approval of the Compensation Amounts for the Board of Directors and the Management Board**

10.1 Approval of the Compensation Amount for the Board of Directors for the Next Term of Office

The Board of Directors proposes to approve the maximum aggregate amount of CHF 1,111,800 as compensation for the Board of Directors for the term of office from the annual general meeting 2024 until the annual general meeting 2025.

Explanations

According to Art. 698 para. 3 item 4 and Art. 735 para. 1 CO as well as Art. 8 lit. e of the Articles of Incorporation of the Company, the general meeting is responsible for approving the aggregate amount of compensation of the Board of Directors for the next term of office.

How is the proposed maximum compensation composed?

The compensation for the Board of Directors is expected to consist of (i) a fee in cash in an aggregate amount of up to CHF 418,200 and (ii) an allocation of restricted share units (RSUs) in an aggregate amount of up to CHF 693,600, for the work of the Board of Directors and its committees. RSUs are subject to a three-year blocking period. For purposes of this proposal, the RSUs will be valued as of the grant date. The maximum amount includes estimated social security contributions, except for mandatory employer contributions to state social security

institutions³. Additional information on the compensation model for the Board of Directors may be found in the Compensation Report 2023.

Does the proposed maximum amount represent an increase compared to the previous reference period?

Yes, compared to the amount approved by shareholders at the annual general meeting 2023 (CHF 1,091,400) the above proposed maximum aggregate compensation the proposed maximum *aggregate* compensation amount for the Board of Directors represents an increase of 1.9%.

Will the effective pay-out be disclosed?

Yes, the actual pay-out to the members of the Board of Directors for the term of office from the annual general meeting 2024 to the annual general meeting 2025 will be disclosed in the Compensation Report 2024 and the Compensation Report 2025.

10.2 Approval of the Fixed Compensation Amount for the Management Board from July 1, 2024 until June 30, 2025

The Board of Directors proposes to approve the maximum aggregate amount of CHF 2,489,303 as fixed compensation for the members of the Management Board for the period from July 1, 2024 until June 30, 2025.

Explanations

According to Art. 698 para. 3 item 4 and Art. 735 para. 1 CO as well as Art. 8 lit. e of the Articles of Incorporation of the Company, the general meeting is responsible for approving the total amount of the compensation of the Management Board.

How is the proposed maximum compensation composed?

The proposed fixed compensation for the Management Board shall consist of a fixed compensation in cash, which includes the base salaries as well as social security and pension contributions, except for the mandatory employer contributions to state social security institutions⁴. Additional information on the compensation model for the Management Board can be found in the Compensation Report 2023.

Does the proposed maximum amount represent an increase compared to the previous reference period?

No, compared to the amount approved for the previous reference period, the above proposed maximum aggregate compensation slightly decreased by 2.7%.

The total maximum compensation amount includes not only the compensation for the four members of the Management Board, but also the amount for the two open positions of the CMO and CFO. The Company is currently assessing when will be the right time to fill these positions.

Will the effective pay-out be disclosed?

Yes, the actual fixed aggregate compensation pay-out to the members of the Management Board for the period from July 1, 2024 until June 30, 2025 will be disclosed in the Compensation Report 2024 and in the Compensation Report 2025.

³ Molecular Partners AG will be obliged to make employer contributions to social security insurance (providing for old age, unemployment, handicap, etc.) in addition to the compensation of the members of the Board of Directors, pursuant to applicable mandatory law. As an estimate based on currently applicable contribution rates and assuming vesting of all RSUs, the employer contributions relating to fixed and long-term compensation are expected not to exceed CHF 52,837 in the aggregate.

⁴ Molecular Partners AG will be obliged to make employer contributions to social security insurance (providing for old age, unemployment, handicap, etc.) in addition to the compensation of the members of the Management Board pursuant to applicable mandatory law. As an estimate based on currently applicable contribution rates the employer contributions are expected not to exceed (i) with respect to the fixed compensation CHF 193,136, and (ii) with respect to the variable compensation (assuming maximum target achievement and maximum vesting of the PSUs) CHF 352,191.

10.3 Approval of the Variable Compensation Amount for the Management Board for the Current Financial Year

The Board of Directors proposes to approve the maximum aggregate amount of CHF 3,913,238 as variable compensation for the members of the Management Board for the current financial year.

Explanations

According to Art. 698 para. 3 item 4 and Art. 735 para. 1 CO as well as Art. 8 lit. e of the Articles of Incorporation of the Company, the general meeting is responsible for approving the total amount of the compensation of the Management Board.

How is the proposed maximum variable compensation composed?

The proposed maximum variable compensation includes the maximum compensation for the Management Board. The proposed maximum variable compensation consists of a variable short-term compensation in cash (bonus) and a variable long-term incentive (LTI) compensation in the form of performance share units (PSUs), as well as estimated social security and pension contributions, except for the mandatory employer contributions to state social security institutions.

Does the proposed maximum amount represent an increase compared to the previous reference period?

Yes, compared to the amount approved by shareholders at the annual general meeting 2023 (CHF 3,853,656) for the financial year 2023 for the Management Board, the proposed maximum aggregate compensation amount for the Management Board represents an increase of 1.5%.

The total maximum compensation amount includes not only the compensation for the four members of the Management Board, but also the amount for the two open positions of the CMO and CFO. The Company is currently assessing when will be the right time to fill these positions.

What are the key elements of the PSU plan and how are PSUs valued for the purpose of this proposal?

PSUs are subject to a three-year vesting period. At the vesting date, the members of the Management Board may receive between zero and 1.5 of the Company shares per PSU based on the achievement of predetermined performance criteria for the financial year 2024. The PSUs will be valued as of the grant date. For purposes of this proposal, the valuation will be based on the issuance of 1.5 shares for each PSU, i.e., assuming maximum target achievement, however, excluding any share price development over the vesting period. The proposal also assumes maximum target achievement of 150% for the variable short-term compensation (bonus).

Will the effective achievement ratio of the bonus and the long-term compensation (PSUs) be disclosed?

Yes, the Compensation Report 2023 discloses the achievement ratio of the bonus and the PSUs of the past years, and the Company intends to continue disclosing the effective achievement ratio for the financial year 2024 in the Compensation Report 2024.

The annual general meeting 2024 will be conducted in English.

Schlieren, March 26, 2024

William (Bill) Burns, Chairman of the Board of Directors

Organizational Information

Documents

The Annual Report 2023, which is published in English only and includes the Compensation Report as well as the reports of the statutory auditors, is available for inspection at the domicile of Molecular Partners AG, Wagistrasse 14, 8952 Schlieren (Zurich). It is also available on the Company's website: www.molecularpartners.com.

Shareholders Entitled to Vote

Shareholders registered with voting rights in the share register as of April 9, 2024, 5:00 p.m., CEST, will be authorized to participate and vote at the annual general meeting 2024. They will receive their admission card and voting materials upon returning the registration form enclosed to the printed invitation or upon registration under <https://molecularpartners.netvote.ch>. For registration with the registration form, please use the enclosed pre-addressed envelope.

NEW as of this annual general meeting 2024: You now have the option to receive the admission card in electronic form. Please select the preferred option between the mail and electronic form under <https://molecularpartners.netvote.ch>.

Representation and Proxy

Shareholders who do not attend the annual general meeting in person may be represented by their legal representatives, another proxy who need not be a shareholder or by the independent proxy, Anwaltskanzlei Keller AG, Splügenstrasse 8, 8002 Zurich. Shareholders wishing such representation by the independent proxy are asked to sign the enclosed proxy form and to forward it, together with any directives, to the Company's share registrar areg.ch ag (see contact details below). For practical reasons, the decision to be represented by the independent proxy may be revoked by the shareholder in favor of personal attendance or attendance by another shareholder no later than April 12, 2024, 11:59 a.m., CEST.

In the absence of specific voting instructions on the proxy form, general authorization is granted to the independent proxy to vote the shares in favor of the proposals of the Board of Directors. This also applies to proposals which are not included in this invitation and might be submitted during the annual general meeting 2024.

Electronic Proxy and Voting

You have also the option to issue proxies and voting instructions to the independent proxy via the internet. Enter <https://molecularpartners.netvote.ch> in your browser and follow the user prompts on the display. You have the same reply options as with the paper format. You will find your personal access data (ID and password) for the initial registration on the registration form. Electronic instructions and any changes to directives issued electronically may be made until April 12, 2024, 11:59 a.m., CEST.

Entries in the Share Register – Trading of Shares

No entries will be made in the share register in the period from April 10, 2024 until the end of the annual general meeting 2024. However, shares may be traded without restrictions. Shareholders who sell part or all of their shares prior to the annual general meeting 2024 are no longer entitled to vote to that extent.

Future electronic receipt of AGM invitation

If you would like to receive invitations to the Company's annual general meetings electronically in the future, you can access the instruction issuance system under <https://molecularpartners.netvote.ch> and select the option "Delivery method". The login details can be found on the reply slip enclosed to the printed invitation.

Questions

Please direct your administrative questions directly to our share registrar (areg.ch ag, Fabrikstrasse 10, 4614 Hägendorf, Tel +41 62 209 16 60, e-mail: info@areg.ch).

Location

JED Events, Zürcherstrasse 39, 8952 Schlieren, Switzerland



Limited parking spaces available on site, public parking available at train station Schlieren or Wagi shopping within walking distance. JED Events can be reached by public transport, followed by a 3-5 minutes walk.